SCHEMBL13166555

SCHEMBL13166555

O=c1c2cccnc2cnc2ccsc12

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.40
PDPK1 O15530 1/20 0.40
PARP1 P09874 1/20 0.40
MAPT P10636 5/20 0.40
LMNA P02545 2/20 0.38
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
AXL P30530 1/20 0.35
MKNK1 Q9BUB5 1/20 0.35
MKNK2 Q9HBH9 1/20 0.35
POLB P06746 1/20 0.34
NCOA1 Q15788 1/20 0.33
TP53 P04637 1/20 0.33
ALOX15 P16050 1/20 0.33
TSHR P16473 1/20 0.33
OPRK1 P41145 1/20 0.33
HTT P42858 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33
TLR9 Q9NR96 1/20 0.33
TDP1 Q9NUW8 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13166545 0.77 CYP3A4 (0.47) KDM4EMAPTLMNAMEN1KMT2A
SCHEMBL13166528 0.77 LMNA (0.41) KDM4EMAPTLMNAKMT2ANCOA1
SCHEMBL13166536 0.77 MAPT (0.50) KDM4EMAPTLMNAMEN1KMT2A
SCHEMBL13629295 0.75 KDM4E (0.52) KDM4EPDPK1PARP1MAPTLMNA
SCHEMBL13629308 0.73 KDM4E (0.45) KDM4EPARP1MAPTLMNAMEN1
SCHEMBL13629319 0.73 KDM4C (0.47) KDM4EPDPK1PARP1MAPTNCOA1
SCHEMBL13629318 0.70 KDM4E (0.45) KDM4EPARP1MAPTLMNAMEN1
SCHEMBL13166538 0.69 MAPT (0.48) KDM4EMAPTLMNAMEN1KMT2A
SCHEMBL13859959 0.68 MAPT (0.71) KDM4EMAPTLMNAMEN1KMT2A
SCHEMBL11299368 0.67 PDPK1 (0.50) KDM4EPDPK1PARP1MAPTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7790739-B2 receptor tyrosine kinase MET inhibitors; anticancer agents; 8-phenyl-10H-furo[2',3':4,5]cyclohepta[1,2-b]pyridin-10-one Merck & Co., Inc. and Merck Sharp & Dohme Corp. (US) 2010-09-07 US disclosed
US-7790739-B2 receptor tyrosine kinase MET inhibitors; anticancer agents; 8-phenyl-10H-furo[2',3':4,5]cyclohepta[1,2-b]pyridin-10-one Merck & Co., Inc. and Merck Sharp & Dohme Corp. (US) 2010-09-07 US disclosed
US-20090247565-A1 Tyrosine Kinase Inhibitors MERCK SHARP & DOHME CORP. 2009-10-01 US disclosed
US-20090247565-A1 Tyrosine Kinase Inhibitors MERCK SHARP & DOHME CORP. 2009-10-01 US disclosed
WO-2007050380-A2 TYROSINE KINASE INHIBITORS MERCK & CO., INC. (US) 2007-05-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090247565-A1 Tyrosine Kinase Inhibitors ABL1, ERBB2, MET KDM4E 958/4885PDPK1 323/4885PARP1 2302/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.